Literature DB >> 1363051

Differential locomotor interactions between dopamine D1/D2 receptor agonists and the NMDA antagonist dizocilpine in monoamine-depleted mice.

A Svensson1, A Carlsson, M L Carlsson.   

Abstract

Previous work in our laboratory has shown that the non-competitive N-methyl-D-aspartate antagonist dizocilipine (MK-801) interacts synergistically with the mixed dopamine (DA) receptor agonist apomorphine and the DA D 1 agonist SKF 38393 to promote locomotion in monoamine-depleted mice. The purpose of the present study was to compare the roles of DA D 1 and DA D 2 receptors in this interaction. To that end, dizocilpine was given in combination with either the DA D 1 receptor agonist SKF 38393 or the selective DA D 2 receptor agonist quinpirole or the preferential DA D 2 agonist bromocriptine. In general, the locomotor stimulatory effects produced by SKF 38393 were potentiated by dizocilpine, whereas the locomotor stimulation produced by quinpirole and bromocriptine was counteracted. However, baseline activity, which partly depends on how much time is allowed to elapse between administration of the DA agonist and commencement of locomotor recording, and partly on the dose of the DA agonist, seems to be an important factor that determines whether dizocilpine will have a weakening or a potentiating effect. Interestingly, the competitive NMDA antagonist D-CPPene displayed a different pattern of interaction with SKF 38393 and quinpirole in that synergistic effects were observed with both DA agonists, most conspicuously so with the DA D 2 receptor agonist. The results are interpreted in the light of present knowledge of basal ganglia neuroanatomy; they are discussed in relation to the "direct" and "indirect" pathways from the striatum to the thalamus, proposed to form part of positive and negative cortico-striato-thalamo-cortical loops, respectively, as well as to the presumed presynaptic D 2 receptors on corticostriatal glutamatergic neurons.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1363051     DOI: 10.1007/bf01250961

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  45 in total

Review 1.  Striatal inhomogeneities and basal ganglia function.

Authors:  J B Penney; A B Young
Journal:  Mov Disord       Date:  1986       Impact factor: 10.338

2.  The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys.

Authors:  T Klockgether; L Turski; T Honoré; Z M Zhang; D M Gash; R Kurlan; J T Greenamyre
Journal:  Ann Neurol       Date:  1991-11       Impact factor: 10.422

3.  SCH 23390 - the first selective dopamine D-1 antagonist.

Authors:  J Hyttel
Journal:  Eur J Pharmacol       Date:  1983-07-15       Impact factor: 4.432

4.  Concentration-dependent actions of stimulated dopamine release on neuronal activity in rat striatum.

Authors:  G V Williams; J Millar
Journal:  Neuroscience       Date:  1990       Impact factor: 3.590

5.  D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons.

Authors:  C R Gerfen; T M Engber; L C Mahan; Z Susel; T N Chase; F J Monsma; D R Sibley
Journal:  Science       Date:  1990-12-07       Impact factor: 47.728

6.  Motor depression: a new role for D1 receptors?

Authors:  C J Chandler; W Wohab; B S Starr; M S Starr
Journal:  Neuroscience       Date:  1990       Impact factor: 3.590

7.  Stimulation of D2-dopamine receptors in rat neostriatum inhibits the release of acetylcholine and dopamine but does not affect the release of gamma-aminobutyric acid, glutamate or serotonin.

Authors:  J C Stoof; T De Boer; P Sminia; A H Mulder
Journal:  Eur J Pharmacol       Date:  1982-10-22       Impact factor: 4.432

8.  A comparison between the non-competitive NMDA antagonist dizocilpine (MK-801) and the competitive NMDA antagonist D-CPPene with regard to dopamine turnover and locomotor-stimulatory properties in mice.

Authors:  A Svensson; E Pileblad; M Carlsson
Journal:  J Neural Transm Gen Sect       Date:  1991

9.  Bromocriptine potentiates the behavioural effects of directly and indirectly acting dopamine receptor agonists in mice.

Authors:  O F Jenkins; D M Jackson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-10       Impact factor: 3.000

10.  Electrophysiological effects of MK-801 on rat nigrostriatal and mesoaccumbal dopaminergic neurons.

Authors:  J Zhang; L A Chiodo; A S Freeman
Journal:  Brain Res       Date:  1992-09-11       Impact factor: 3.252

View more
  12 in total

1.  Interaction between glutamatergic and dopaminergic tone in the nucleus accumbens of mice: evidence for a dual glutamatergic function with respect to psychomotor control.

Authors:  A Svensson; M L Carlsson; A Carlsson
Journal:  J Neural Transm Gen Sect       Date:  1992

2.  Crucial role of the accumbens nucleus in the neurotransmitter interactions regulating motor control in mice.

Authors:  A Svensson; M L Carlsson; A Carlsson
Journal:  J Neural Transm Gen Sect       Date:  1995

3.  The muscarine antagonist methscopolamine and the NMDA antagonist AP-5 injected unilaterally into the nucleus accumbens cause mice to rotate in opposite directions.

Authors:  A Svensson; M L Carlsson
Journal:  J Neural Transm Gen Sect       Date:  1995

Review 4.  Mechanisms of action of atypical antipsychotic drugs: a critical analysis.

Authors:  B J Kinon; J A Lieberman
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

5.  MK801-induced locomotor activity in preweanling and adolescent male and female rats: role of the dopamine and serotonin systems.

Authors:  Sanders A McDougall; Matthew G Apodaca; Ginny I Park; Angie Teran; Timothy J Baum; Nazaret R Montejano
Journal:  Psychopharmacology (Berl)       Date:  2020-05-22       Impact factor: 4.530

6.  The AMPA antagonists NBQX and GYKI 52466 do not counteract neuroleptic-induced catalepsy.

Authors:  B Zadow; W J Schmidt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-01       Impact factor: 3.000

7.  Are the disparate pharmacological profiles of competitive and un-competitive NMDA antagonists due to different baseline activities of distinct glutamatergic pathways? (Hypothesis).

Authors:  M L Carlsson
Journal:  J Neural Transm Gen Sect       Date:  1993

8.  The selective 5-HT2A receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse--implications for psychosis.

Authors:  M L Carlsson
Journal:  J Neural Transm Gen Sect       Date:  1995

9.  Memantine, amantadine, and L-deprenyl potentiate the action of L-dopa in monoamine-depleted rats.

Authors:  G Skuza; Z Rogoz; G Quack; W Danysz
Journal:  J Neural Transm Gen Sect       Date:  1994

10.  The non-NMDA glutamate receptor antagonist GYKI 52466 counteracts locomotor stimulation and anticataleptic activity induced by the NMDA antagonist dizocilpine.

Authors:  W Hauber; R Andersen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-11       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.